Preclinical data demonstrating hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801 can be reproducibly synthesized and is suitable for human use.
Preclinical data demonstrating that our hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect activated macrophages and microglia with high sensitivity and specificity in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis (MS).
Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PET
Hydroxyl Dendrimer Therapeutics Reduce Toxicity in Targeted Delivery to Plexiform Neurofibroma
Safety and Tolerability of a Single Subcutaneous Dose of Anti-Angiogenesis Drug to Treat Neovascular Age-related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME)
Development of a novel hydroxyl dendrimer SPECT tracer, 111In-D6-B483, for selective imaging of brain tumors
Development of 18F-OP-801: A Novel Hydroxyl Dendrimer PET Tracer for Imaging Maladaptive Inflammation in the Whole Body and Brain
Single Subcutaneous (or Oral) Dose of Anti-Angiogenesis Drug Safely Suppresses Choroidal Neovascularization Comparable to Intravitreal Aflibercept
Selective Targeting and Imaging of Orthotopic Glioblastoma after a Single Systemic Dose of a Novel Hydroxyl Dendrimer Radionuclide
Hepatocyte Targeted Therapy to Enhance Efficacy and Safety of Drugs for Liver Diseases